4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage genetic medicines company, announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston from September 26-28, 2024. The presentation will cover preclinical data on 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators.
Details:
- Title: Transgene expression and CFTR channel function in human bronchial epithelial cells following addition of CFTR modulators and 4D-710
- Poster Session: Poster 344
- Date/Time: Friday, September 27, 2024 (1:15 – 2:15 p.m. ET)
- Presenter: Melissa A. Calton, Ph.D., VP, Early-Stage Product Development at 4DMT
The presentation will be available on the 4DMT website.
4D Molecular Therapeutics (Nasdaq: FDMT), una società di terapie genetiche in fase clinica, ha annunciato una presentazione poster alla Conferenza Nordamericana sulla Fibrosi Cistica 2024 (NACFC) che si terrà a Boston dal 26 al 28 settembre 2024. La presentazione tratterà dati preclinici su 4D-710 per la malattia polmonare da fibrosi cistica in combinazione con i modulatori del CFTR.
Dettagli:
- Titolo: Espressione del transgene e funzione del canale CFTR in cellule epiteliali bronchiali umane dopo l'aggiunta di modulatori del CFTR e 4D-710
- Sessione Poster: Poster 344
- Data/Ora: Venerdì, 27 settembre 2024 (1:15 – 2:15 p.m. ET)
- Relatrice: Melissa A. Calton, Ph.D., VP dello Sviluppo Prodotti in Fase Iniziale di 4DMT
La presentazione sarà disponibile sul sito web di 4DMT.
4D Molecular Therapeutics (Nasdaq: FDMT), una empresa de medicamentos genéticos en etapa clínica, anunció una presentación de póster en la Conferencia Norteamericana de Fibrosis Quística 2024 (NACFC) en Boston del 26 al 28 de septiembre de 2024. La presentación cubrirá datos preclínicos sobre 4D-710 para la enfermedad pulmonar por fibrosis quística en combinación con moduladores de CFTR.
Detalles:
- Título: Expresión de transgenes y función de canales CFTR en células epiteliales bronquiales humanas tras la adición de moduladores de CFTR y 4D-710
- Sesión de Póster: Póster 344
- Fecha/Hora: Viernes, 27 de septiembre de 2024 (1:15 – 2:15 p.m. ET)
- Presentadora: Melissa A. Calton, Ph.D., VP de Desarrollo de Productos en Etapa Temprana en 4DMT
La presentación estará disponible en el sitio web de 4DMT.
4D Molecular Therapeutics (Nasdaq: FDMT)은 임상 단계의 유전자 치료 회사로, 2024년 9월 26일부터 28일까지 보스턴에서 열리는 2024 북미 낭포성 섬유증 학회 (NACFC)에서 포스터 발표를 하겠다고 발표했습니다. 발표에서는 CFTR 조절제와 함께 사용되는 낭포성 섬유증 폐 질환에 대한 4D-710의 전임상 데이터를 다룰 예정입니다.
세부 사항:
- 제목: CFTR 조절제와 4D-710 추가 후 인간 기관지 상피 세포에서의 유전자 발현 및 CFTR 채널 기능
- 포스터 세션: 포스터 344
- 날짜/시간: 2024년 9월 27일 금요일 (오후 1:15 – 2:15 ET)
- 발표자: Melissa A. Calton, Ph.D., 4DMT의 초기 제품 개발 부사장
발표는 4DMT 웹사이트에서 확인할 수 있습니다.
4D Molecular Therapeutics (Nasdaq: FDMT), une entreprise de médicaments génétiques en phase clinique, a annoncé une présentation de poster lors de la Conférence Nord-Américaine sur la Fibrose Kystique 2024 (NACFC) à Boston du 26 au 28 septembre 2024. La présentation couvrira des données précliniques sur 4D-710 pour la maladie pulmonaire de la fibrose kystique en combinaison avec des modulateurs de CFTR.
Détails :
- Titre : Expression de transgène et fonction du canal CFTR dans les cellules épithéliales bronchiques humaines après l'ajout de modulateurs de CFTR et de 4D-710
- Session de Poster : Poster 344
- Date/Heure : Vendredi, 27 septembre 2024 (13:15 – 14:15 ET)
- Présentatrice : Melissa A. Calton, Ph.D., VP du Développement de Produits en Phase Précoce chez 4DMT
La présentation sera disponible sur le site web de 4DMT.
4D Molecular Therapeutics (Nasdaq: FDMT), ein Unternehmen für genetische Medikamente in der klinischen Phase, gab eine Posterpräsentation auf der 2024 Nordamerikanischen Fibrosekonferenz (NACFC) in Boston vom 26. bis 28. September 2024 bekannt. Die Präsentation wird präklinische Daten zu 4D-710 für die pulmonale Mukoviszidose in Kombination mit CFTR-Modulatoren behandeln.
Details:
- Titel: Transgen-Expression und CFTR-Kanal-Funktion in menschlichen bronchialen Epithelzellen nach Zugabe von CFTR-Modulatoren und 4D-710
- Poster-Sitzung: Poster 344
- Datum/Uhrzeit: Freitag, 27. September 2024 (1:15 – 2:15 p.m. ET)
- Referent: Melissa A. Calton, Ph.D., VP für frühzeitige Produktentwicklung bei 4DMT
Die Präsentation wird auf der 4DMT-Website verfügbar sein.
- 4D-710 preclinical data presentation at a major conference.
- Potential positive impact on cystic fibrosis treatment.
- No immediate financial or clinical trial results impact reported.
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston, Massachusetts on September 26-28, 2024.
2024 NACFC Poster Presentation Details:
| Title: | Transgene expression and CFTR channel function in human bronchial epithelial cells following addition of CFTR modulators and 4D-710 |
| Poster Session: | Poster 344 |
| Date/Time: | Friday, September 27, 2024 (1:15 – 2:15 p.m. ET) |
| Presenter: | Melissa A. Calton, Ph.D., VP, Early-Stage Product Development at 4DMT |
The presentation will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications
About 4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine Smith
Inizio Evoke Comms
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
What is the significance of 4D-710's presentation at the 2024 NACFC?
When and where is 4D Molecular Therapeutics presenting at the NACFC?
Who will present the 4D-710 data at the NACFC?
What is the focus of the 4D-710 poster presentation?
Where can I find the presentation details for 4D-710?
